Gujarat Themis Biosyn Expands into Global CDMO via MicroBioPharm Japan Acquisition
Gujarat Themis Biosyn Ltd 路 Investor Presentation 路 16 Nov 2026, 9:56 pm
Gujarat Themis Biosyn Expands into Global CDMO via MicroBioPharm Japan Acquisition Gujarat Themis Biosyn completed the acquisition of MicroBioPharm Japan for INR 1,351 Cr, financed via INR 727 Cr QIP and INR 624 Cr mezzanine debt, alongside INR 632 Cr debt refinancing. Standalone fermentation capacity doubled from 450 KL to 990 KL. In Q2 FY27, consolidated operations reported revenue of INR 49.9 Cr, an operating EBITDA loss of INR 0.9 Cr, and a net loss of INR 13.8 Cr, impacted by INR 15.57 Cr in unrealized forex losses, higher acquisition financing costs, and partial 13-day MBJ consolidation.
Original exchange filing (PDF)
More announcements from Gujarat Themis Biosyn Ltd
- Recording of Analysts Meet held on 16.11.2026 路 17 Nov 2026
- Please refer to the attachment 路 16 Nov 2026
- Please refer to the intimation of resignation of Company Secretary & Compliance Officer. 路 15 Nov 2026
- Please refer to the attachment 路 14 Nov 2026
- Kindly refer to the Un-audited Standalone & Consolidated Financial Results for the quarter and half year ended 30.09.2026 路 14 Nov 2026
- Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Outcome of the Board Meeting held on 14.11.2026 路 14 Nov 2026
- GUJTHEM : 14-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 04, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 14, 2026, To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 14 Nov 2026
